March 20, 2020 / 7:19 AM / 10 days ago

BRIEF-Oncopeptides Updates On Coronavirus Impact On Melflufen Clinical Program

March 20 (Reuters) - Oncopeptides AB:

* ONCOPEPTIDES PROVIDES UPDATE REGARDING COVID-19 IMPACT ON THE MELFLUFEN CLINICAL PROGRAM

* PIVOTAL PHASE 2 HORIZON STUDY WILL NOT BE AFFECTED AND FDA SUBMISSION PLANS ARE ON TRACK FOR A FILING LATE Q2.

* PHASE 3 OCEAN STUDY WITH 423 OUT OF 450 PLANNED PATIENTS ENROLLED WILL REMAIN OPEN FOR PATIENT ENROLMENT

* TOPLINE RESULTS ARE EXPECTED TO BE ONLY SLIGHTLY DELAYED.

* RECRUITMENT FOR OTHER ONGOING CLINICAL STUDIES WILL BE PUT ON TEMPORARY PAUSE FOR PATIENT SAFETY REASONS

* INITIATION OF NEW STUDIES INCLUDING LIGHTHOUSE IS EXPECTED TO BE DELAYED.

* BRIDGE STUDY HAS PUT RECRUITMENT ON TEMPORARY PAUSE.

* AL AMYLOIDOSIS STUDY HAS PUT RECRUITMENT ON TEMPORARY PAUSE.

* NO NEW STUDIES WILL BE INITIATED DURING THIS PERIOD Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below